Zubsolv – Medicated Assisted Treatment For Opiate Addiction

Zubsolv combines naloxone and buprenorphine to make a prescription medication meant to treat opioid addiction. Makers strongly recommend it with a comprehensive treatment program involving cognitive behavioral therapy, counseling, and recovery support resources.

  • The FDA approved it in October 2016.

Pharmacologically it is designated as a partial opioid agonist. It is because it offers the benefits of naloxone (aka Narcan). In addition, it blocks the euphoric effects of heroin and painkillers and buprenorphine.

  • While buprenorphine also prevents addicts from getting high off legal and illegal opioids, it additionally reduces the severity of cravings and withdrawal symptoms.

The manufacturer information instructs physicians to prescribe it only when addicts experience withdrawal symptoms to circumvent precipitating or facilitating withdrawal. Tablets should be placed under the tongue until they dissolve completely.

When patients take two tablets, they should place each tablet in a different place under the tongue simultaneously. Additionally, tablets should not be crushed, swallowed, or chewed.

  • Tablets may cause life-threatening side effects if they are crushed, mixed with water, and injected intravenously.

Since they contain buprenorphine, an opioid derivative, the potential for abuse exists. It is especially true with benzodiazepines, alcohol, or other CNS depressants.

Adverse events reported during clinical trials include;

  • nausea/vomiting
  • headache
  • gastrointestinal problems
  • insomnia
  • excessive sweating
  • swelling of the hands and feet

A few serotonin syndrome cases exist with concomitant use of antidepressants (SSRIs) and opioids. For this reason, people taking this drug may not be able to take SSRIs during treatment.

This drug and Suboxone are similar medications explicitly designed to help opioid abusers avoid relapsing. Both contain naloxone and buprenorphine, and both come in sublingual form. Alternately, differences between it and Suboxone include:

  • It is menthol/minty-tasting
  • Suboxone is orange-flavored.
  • They are small tablets; Suboxone is a piece of film.
  • Tablets contain less buprenorphine than Suboxone sublingual film strips.

Studies show Zubsolv presents enhanced bioavailability properties over Suboxone. When a medication is readily bioavailable, the body can efficiently absorb and utilize the medication ingredients to expedite its benefits.

  • One study found that subjects preferred the minty flavor over Suboxone citrus flavor.

Lengths of time patients spend participating in a recovery program that includes this drug, and behavioral therapy varies greatly among addicts. Therefore, it should be considered an individual decision based heavily on the recommendation of an addiction specialist, counselor, and or physician.

When deciding to take either of these drugs, you should be aware that both contain an opioid, potentially conducive to dependence. Also, it would help if you never stopped taking these medications without discussing them with your prescribing doctor. Never use them on an occasional basis. The efficacy partially comes from the resolve of the addict to defeat their opioid addiction and avoid relapsing.